# Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention

> **NCT05764993** · PHASE2 · UNKNOWN · sponsor: **Rochester General Hospital** · enrollment: 40 (estimated)

## Conditions studied

- COPD Exacerbation Acute

## Interventions

- **BIOLOGICAL:** CUVITRU - Ig subcutaneous human 20%
- **OTHER:** Standard Medical Therapy

## Key facts

- **NCT ID:** NCT05764993
- **Lead sponsor:** Rochester General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05764993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05764993, "Prevalence of Humoral Dysfunction in Pts With Frequent Exacerbations of COPD, and the Effect of SCIgR for Prevention". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05764993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*